Quick Summary
- Oral finasteride works for hair retention but causes systemic 5-alpha reductase inhibition, which produces libido, mood, and sexual side effects in a meaningful percentage of users.
- Topical anti-androgens block the androgen receptor at the scalp directly, with minimal systemic absorption.
- RU58841 has 35+ years of underground use data and is the most validated topical anti-androgen for scalp use.
- Clascoterone (CB-03-01) is the first FDA-approved topical anti-androgen for acne, with strong off-label evidence for hair retention.
- The Natural Plus angle: protect the hair locally so the rest of your hormonal protocol is not constrained by a finasteride decision you might regret.
The finasteride question is one of the most consequential in male optimization. Hair retention matters. So does libido. So does mood. So does the ability to run testosterone or other androgen protocols without compounding DHT suppression. Oral finasteride forces a tradeoff between those things. Topical anti-androgens largely dissolve the tradeoff.
This is not an article about whether finasteride works. It does. It is an article about whether you have to take it systemically to protect your hair, and the answer is no.
The Biochemistry: Why Hair Loss Happens And Why Topical Works
Male pattern hair loss is driven by DHT binding to androgen receptors in genetically susceptible hair follicles, primarily on the top of the scalp. Over time, the follicles miniaturize. The hair becomes thinner, shorter, and eventually does not produce a visible shaft.
There are three pharmacological levers to interrupt this. You can suppress DHT production systemically (finasteride, dutasteride). You can block the androgen receptor systemically (bicalutamide, flutamide). Or you can block the androgen receptor locally at the scalp follicle. The third option is what topical anti-androgens do, and it is the option that minimizes systemic tradeoffs.
The pharmacokinetic question is simple: can the topical compound reach the follicle at therapeutic concentration without entering systemic circulation at meaningful concentration? For the compounds covered here, the answer is yes — if the formulation is right.
The Tony Huge Laws of Biochemistry Physics Application
This is Law 1 of the Tony Huge Laws of Biochemistry Physics — Governors vs Accelerators — applied locally rather than systemically. DHT at the follicle is a governor on hair growth. The same DHT systemically is an accelerator for libido, muscle preservation, and mood. The leverage move is to remove the governor only where it operates against you. Local AR blockade at the scalp protects the hair without sacrificing the systemic DHT that drives the rest of your physiology. That asymmetry is the entire point.
The Three Topical Anti-Androgens
RU58841. A non-steroidal androgen receptor antagonist originally developed by Roussel-Uclaf in the 1980s for prostate cancer. Development was abandoned for systemic use, but the compound found a second life as a topical hair-loss intervention. Underground users have been running RU58841 since the 1990s. The compound has a short half-life when systemically absorbed (which is why it failed orally), but that short half-life is the feature for topical use — anything that does penetrate systemically clears fast.
Clascoterone (CB-03-01). The first FDA-approved topical anti-androgen, approved in 2020 for acne under the brand Winlevi. It is structurally similar to spironolactone but designed to inactivate after topical absorption to avoid systemic effects. The off-label hair loss data is strong. The cream is expensive and concentration may be suboptimal for scalp use, but the safety data is the cleanest in the topical AR class.
Pyrilutamide (KX-826). A newer non-steroidal AR antagonist developed specifically for topical scalp use. Phase 3 trials completed in China with positive results. Approval and Western availability lagged but the compound is increasingly available through gray-market channels. The trial data showed hair count improvement comparable to oral finasteride with minimal systemic exposure.
Natural Plus Protocol
Different compounds require different protocols. The general principles apply across all three.
- Vehicle matters. Topical anti-androgens require a vehicle that penetrates the stratum corneum to reach the follicle. KB (Kirkland-Buchwald) solution, ethanol-based vehicles, or PG-ethanol mixtures are the standard. A bad vehicle wastes the compound on the surface.
- RU58841 protocol: 5% solution, 1mL applied to the scalp once daily, typically at night. Massage in, leave overnight, wash out in the morning. Some users dose every other day for tolerance.
- Clascoterone protocol: Apply the 1% cream as marketed, twice daily, to affected scalp areas.
- Pyrilutamide protocol: 0.5% solution, twice daily as used in the Phase 3 trials.
- Minoxidil stacking: Topical minoxidil 5% solution or foam is independent mechanism (vasodilation + direct hair cycle modulation). It is the standard pair with any AR antagonist.
- Bloodwork: Pull testosterone, free testosterone, DHT, and a basic CMP at baseline and 12 weeks. Systemic absorption should be minimal but bloodwork verifies.
Stacking Recommendations
Topical anti-androgens stack well with independent mechanism interventions:
- Topical minoxidil 5% — vasodilation and direct hair cycle modulation. Independent mechanism. Always pair.
- GHK-Cu peptide topical — copper peptide stimulates follicle stem cells and reduces inflammation around miniaturizing follicles. See GHK-Cu hair regrowth.
- Microneedling — mechanical stimulation increases topical absorption and triggers Wnt signaling in follicles. See microneedling peptides.
- Oral nutrients — biotin, zinc, iron sufficiency. Address deficiencies that compound hair loss independently of androgen pathway.
Target Audience
Topical anti-androgens make sense for: men running testosterone or other androgen protocols who want hair protection without DHT suppression, men who tried oral finasteride and got sexual or mood side effects (post-finasteride syndrome population), men in their 20s and 30s who want hair retention without committing to chronic systemic 5-AR inhibition, and anyone whose hair loss is in early-to-moderate Norwood stages.
Timeline / Results
| Timeframe | What to Expect |
|---|---|
| Month 1-2 | Some early shedding as miniaturized follicles cycle; this is normal. |
| Month 3 | Shedding stabilizes, early thickening at the hairline and crown. |
| Month 6 | Visible thickening, hair count improvement, retention confirmed. |
| Month 12 | Sustained retention, full effect plateau, decision point on maintenance. |
Interesting Perspectives
The most overlooked element of topical anti-androgen protocols is the vehicle. Underground users obsess over which compound to use and pay very little attention to which vehicle they dissolve it in. The vehicle determines whether the compound reaches the follicle or sits on the skin and evaporates. KB solution, PG-ethanol, and certain liposomal vehicles produce dramatically different absorption profiles. The Reddit posts about “RU58841 not working” are mostly vehicle problems, not compound problems.
Contrarian take: the medical establishment has been recommending oral finasteride to twenty-year-olds for decades while topical alternatives with equivalent efficacy and dramatically better systemic safety profiles have been available the entire time. The reason topicals were not the standard recommendation is largely regulatory and economic — they were not FDA-approved for hair loss, they did not have pharma marketing budgets behind them, and finasteride was easy to prescribe. That is not a clinical judgment. That is a market failure.
Cross-domain connection: the same logic applies to other local-vs-systemic decisions. Topical NSAIDs for joint pain instead of oral. Topical corticosteroids for skin inflammation instead of oral. Local injection of platelet-rich plasma instead of systemic anti-inflammatory protocols. The principle is identical — apply the intervention where you need it, not everywhere.
The hypocrisy angle: the same medical community that warned bodybuilders for thirty years about the dangers of systemic anti-androgens prescribed oral finasteride freely to men in their twenties without seriously characterizing the post-finasteride syndrome cluster until users self-organized to document it. The asymmetry of caution is striking.
FAQ
Are topical anti-androgens as effective as oral finasteride? For most Norwood 1-3 patterns, yes. The hair retention data is comparable. Severe Norwood 5+ patterns may require systemic intervention.
Is RU58841 safe? It has 35+ years of underground use data with no major systemic safety signal at topical doses. Short systemic half-life is a feature for topical use. Formal Western trials are limited.
Can I stack topical anti-androgens with testosterone? Yes — that is one of the main use cases. Local scalp AR blockade protects hair while systemic testosterone supports the rest of the body.
Do I need oral finasteride at all if I use topicals? Most users find topical AR blockade plus minoxidil sufficient. Oral 5-AR inhibition is reserved for cases that need broader DHT suppression or fail topical-only protocols.
What is the difference between RU58841, clascoterone, and pyrilutamide? RU58841 is the longest-used underground option with strong empirical data but no FDA approval. Clascoterone is FDA-approved for acne with off-label hair use. Pyrilutamide is newer with strong Phase 3 trial data and growing availability.
Cross-Reference
For hair-specific stacking see GHK-Cu hair regrowth and microneedling peptides. For DHT and estrogen balance see DHT and estrogen balance. For foundational hormone optimization see Protocol: Hormones and the Enhanced Athlete Protocol hub.